哮喘新疗法的研究可分为两大类。一类为长效β_2-激动剂、安全性较好的皮质类固醇类吸人剂及更具有特异性的磷酸二酯酶抑制剂,另一类是基于目前对哮喘病理生理学的认识而开发的药物。已证明哮喘是一种气道炎症,因此研究的重点在于寻找既能缓解平滑肌痉挛又有抗炎作用的新药。目前正努力开发一些受体拮抗剂或新生成的膜衍生介质的合成抑制剂。 Studies of new therapies for asthma can be divided into two broad categories. One is a long-acting beta 2-agonist, a safer corticosteroid inhaler and a more specific phosphodiesterase inhibitor, and the other is a drug developed based on the current understanding of the pathophysiology of asthma . Asthma has been shown to be an inflammation of the airways, so the focus of the study is to find new drugs that both relieve smooth muscle spasms and have an anti-inflammatory effect. At present, efforts are being made to develop synthetic inhibitors of some receptor antagonists or newly formed membrane-derived mediators.